Valuation: Exelixis, Inc.

Capitalization 11B 9.38B 8.76B 8.24B 15.17B 997B 16.57B 102B 39.65B 470B 41.29B 40.42B 1,714B P/E ratio 2025 *
16x
P/E ratio 2026 * 13.8x
Enterprise value 10.43B 8.88B 8.3B 7.81B 14.37B 944B 15.7B 96.84B 37.56B 445B 39.12B 38.29B 1,624B EV / Sales 2025 *
4.47x
EV / Sales 2026 * 3.79x
Free-Float
98.21%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Exelixis, Inc.

1 day-1.23%
1 week-7.84%
Current month-7.45%
1 month-3.47%
3 months+4.42%
6 months-1.71%
Current year+22.76%
More quotes
1 week 40.66
Extreme 40.66
44.59
1 month 40.66
Extreme 40.66
44.91
Current year 31.9
Extreme 31.9
49.62
1 year 31.9
Extreme 31.9
49.62
3 years 15.32
Extreme 15.32
49.62
5 years 14.87
Extreme 14.87
49.62
10 years 3.55
Extreme 3.55
49.62
More quotes
Manager TitleAgeSince
Chief Executive Officer 64 21/07/2010
Director of Finance/CFO 57 14/07/2015
Chief Operating Officer 62 31/01/2016
Director TitleAgeSince
Director/Board Member 68 31/01/2004
Director/Board Member 81 31/07/2004
Chairman 76 31/12/1997
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.23%-7.84%+16.70%+154.70% 11B
-0.48%-2.31%+29.68%+105.96% 54.11B
+0.91%-3.43%+175.04%+885.05% 42.02B
+0.70%+4.04%+66.46%+19.35% 39.6B
-1.24%-1.50%-21.24%-46.81% 22.8B
-1.52%-0.84%+40.08%-36.97% 19.5B
0.00%+2.64%+88.09%-34.80% 17.76B
+6.05%+0.32%+95.60%+196.08% 14.73B
-2.33%-4.04%-1.46%+349.36% 13.55B
+0.02%-1.02%+87.67%+814.16% 12.98B
Average +0.09%-1.53%+57.66%+240.61% 24.8B
Weighted average by Cap. +0.11%-1.27%+65.17%+246.62%
See all sector performances

Financials

2025 *2026 *
Net sales 2.33B 1.99B 1.86B 1.75B 3.22B 211B 3.52B 21.69B 8.41B 99.68B 8.76B 8.58B 364B 2.61B 2.23B 2.08B 1.96B 3.6B 237B 3.94B 24.28B 9.42B 112B 9.81B 9.6B 407B
Net income 716M 610M 570M 536M 987M 64.86B 1.08B 6.65B 2.58B 30.57B 2.69B 2.63B 112B 776M 661M 617M 581M 1.07B 70.26B 1.17B 7.2B 2.79B 33.12B 2.91B 2.85B 121B
Net Debt -580M -494M -461M -434M -799M -52.49B -873M -5.38B -2.09B -24.74B -2.17B -2.13B -90.27B -1.1B -941M -879M -827M -1.52B -100B -1.66B -10.26B -3.98B -47.16B -4.14B -4.06B -172B
More financial data * Estimated data
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Employees
1,147
More about the company
Date Price Change Volume
12/12/25 40.88 $ -1.23% 2,569,223
11/12/25 41.39 $ +0.78% 2,794,345
10/12/25 41.07 $ -1.91% 3,239,688
09/12/25 41.87 $ -0.71% 2,890,361
08/12/25 42.17 $ -4.94% 3,667,225

Delayed Quote Nasdaq, December 12, 2025 at 09:00 pm

More quotes
Trader
Investor
Global
Quality
ESG MSCI
BB
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
40.88USD
Average target price
44.94USD
Spread / Average Target
+9.94%
Consensus

Quarterly revenue - Rate of surprise